Immunomodulatory therapy in paediatric inflammatory bowel disease
Abstract
Immunomodulatory drugs are indispensable in the treatment of children with both Crohn’s disease and ulcerative colitis, especially in maintaining remission. Among them, azathioprine and 6-mercaptopurine are the most effective in this respect and they elicit less adverse reactions compared to other immunomodulatory drugs. A very important benefit of immunomodulatory therapy is that they are steroid-sparing agents, which is especially essential in developing children. Although, due to their slow onset of action, most of these drugs are not appropriate for induction of remission, their early introduction may be helpful in faster tapering of steroids and bridging them to azathioprine or 6-mercaptopurine. In this review the mechanism of action, evidence based therapeutical efficiency and adverse reactions to immunomodulatory drugs will be reviewed.
Downloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
